OPALEYE MANAGEMENT INC.
Adviser information for OPALEYE MANAGEMENT INC. last updated from Form ADV on March 26th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.
Advisory Business
Type of Organization | Corporation |
---|---|
Fiscal Year End | DECEMBER |
Legal Location | Massachusetts, United States |
Employees
Total Number of Employees | 4 |
---|---|
Investment Advisory/Research | 3 |
Registered Broker-Dealer Representatives | 0 |
Registered State Investment Advisers | 0 |
Licensed Agents of an Insurance Company | 0 |
No. of Firms/People that Solicit Clients | 0 |
RAUM
Provides Management of Securities Portfolios | Yes |
---|
Type | Accounts | RAUM |
---|---|---|
Discretionary | 2 | $432.5M |
Non-Discretionary | 0 | $0 |
Total | 2 | $432.5M |
Clients
Type | Number | RAUM |
---|---|---|
Individuals | 0 | $0 |
HNW Individuals | 0 | $0 |
Banking or thrift institutions | 0 | $0 |
Investment companies | 0 | $0 |
Business development companies | 0 | $0 |
Pooled investment vehicles | 1 | $421.9M |
Pension and profit sharing plans | 0 | $0 |
Charitable organizations | 0 | $0 |
State or municipal gov entities | 0 | $0 |
Other investment advisers | <5 | $10.6M |
Insurance companies | 0 | $0 |
Sovereign wealth funds and foreign official institutions | 0 | $0 |
Corporations or other businesses | 0 | $0 |
Other | 0 | $0 |
Type | Number |
---|---|
No. of Non-RAUM Clients | 0 |
No. of Non-U.S. Clients | 50 |
Services
Advisory Services | Portfolio management for pooled investment vehiclesPortfolio management for businesses or institutional clients |
---|---|
Compensation | % of AUMPerformance-based fees |
Principal Office
ONE BOSTON PLACE26TH FLOOR
BOSTON
MA
United States
Monday - Friday, 9:00 AM TO 5:00 PM, ET
Tel: 617-229-5085, Fax: None
Chief Compliance Officer
JAMES SILVERMAN
PRESIDENT
ONE BOSTON PLACE
26TH FLOOR
BOSTON
MA
United States
Tel:
617-229-5085
J**@*************M
(Full email address available in API data)
Industry Affiliates
OPALEYE GP LLC | Other investment adviser, including financial plannersSponsor, GP, manager of pooled investment vehicles |
Private Funds
Name | Type | Assets $USD | Min Investment $USD | No. Owners |
---|---|---|---|---|
OPALEYE, L.P. | Hedge Fund | $421.8M | $0.3M | 63 |
Control Persons
Name | Type | Entity | Title | Since | Ownership |
---|---|---|---|---|---|
SILVERMAN, JAMES, AARON | Individual | – | PRESIDENT/CHIEF COMPLIANCE OFFICER | 02/1996 | > 75% |
No. Employees, Historic
RAUM, Historic
No. Clients, Historic
Holdings
From latest 13F, filed August 14th, 2024 for period ending June 30th, 2024
Name | Class | Value $USD | # Shares | Private Fund |
---|---|---|---|---|
4D MOLECULAR THERAPEUTICS INC | COM | 7M | 346K | – |
ABCELLERA BIOLOGICS INC | COM | 592K | 200K | – |
ACELYRIN INC | COM | 7M | 2M | – |
AEROVATE THERAPEUTICS INC | COM | 730K | 440K | – |
ALIGOS THERAPEUTICS INC | COM | 441K | 1M | – |
ALLAKOS INC | COM | 3M | 3M | – |
APPLIED THERAPEUTICS INC' | COM | 8M | 2M | – |
ARVINAS INC | COM | 15M | 555K | – |
BIODESIX INC | COM | 6M | 4M | – |
CARGO THERAPEUTICS INC | COM | 9M | 556K | – |
CATALYST PHARMACEUTICALS INC | COM | 10M | 640K | – |
CODEXIS INC | COM | 11M | 3M | – |
CYTOKINETICS INC | COM NEW | 11M | 199K | – |
DESIGN THERAPEUTICS INC | COM | 687K | 205K | – |
EDGEWISE THERAPEUTICS INC | COM | 10M | 580K | – |
ETON PHARMACEUTICALS INC | COM | 8M | 2M | – |
FULCRUM THERAPEUTICS INC | COM | 2M | 285K | – |
GOSSAMER BIO INC | COM | 4M | 4M | – |
GOSSAMER BIO INC | NOTE 5.000% 6/0 | 4M | – | – |
HARROW HEALTH INC | COM | 83M | 4M | – |
IBIO INC | COM NEW | 791K | 375K | – |
IMMUNOME INC | COM | 13M | 1M | – |
INTELLIA THERAPEUTICS INC | COM | 5M | 218K | – |
IOVANCE BIOTHERAPEUTICS INC | COM | 7M | 897K | – |
JASPER THERAPEUTICS INC | COM NEW | 9M | 392K | – |
KARYOPHARM THERAPEUTICS INC | NOTE 3.000%10/1 | 4M | – | – |
KARYOPHARM THERAPEUTICS INC | COM | 1M | 1M | – |
KEROS THERAPEUTICS INC | COM | 17M | 368K | – |
LEXICON PHARMACEUTICALS INC | COM NEW | 3M | 2M | – |
LIQUIDIA CORPORATION | COM NEW | 4M | 325K | – |
LYELL IMMUNOPHARMA INC | COM | 2M | 2M | – |
NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | 6M | 315K | – |
NURIX THERAPEUTICS INC | COM | 9M | 419K | – |
NUVALENT INC | COM | 4M | 59K | – |
OCULAR THERAPEUTIX INC | COM | 36M | 5M | – |
PMV PHARMACEUTICALS INC | COM | 770K | 475K | – |
PROTAGONIST THERAPEUTICS INC | COM | 4M | 105K | – |
PROTARA THERAPEUTICS INC | COM STK | 5M | 2M | – |
REGULUS THERAPEUTICS INC | COM | 3M | 1M | – |
RELMADA THERAPEUTICS INC | COM | 2M | 600K | – |
RENEO PHARMACEUTICALS INC | COM | 249K | 165K | – |
RHYTHM PHARMACEUTICALS INC | COM | 21M | 515K | – |
SAVARA INC | COM | 3M | 715K | – |
SYROS PHARMACEUTICALS INC | COM NEW | 4M | 865K | – |
TG THERAPEUTICS INC | COM | 41M | 2M | – |
TREVI THERAPEUTICS INC | COM | 8M | 3M | – |
UROGEN PHARMA LTD | COM | 7M | 412K | – |
VAXCYTE INC | COM | 6M | 85K | – |
VENTYX BIOSCIENCES INC | COM | 3M | 1M | – |
VERASTEM INC | COM NEW | 3M | 915K | – |
XOMA CORP DEL | COM NEW | 6M | 250K | – |